<p>投资于能够扭转命运的公司的兴奋感吸引了一些投机者，因此即使是没有收入、没有利润且业绩不佳的公司，也能找到投资者。但现实是，当一家公司每年亏损足够长的时间后，其投资者通常会承担这些损失。亏损的公司尚未证明其盈利能力，最终外部资本的流入可能会枯竭。</p>
<p>与此相反，许多投资者更倾向于关注像 <strong>Halozyme Therapeutics</strong>（NASDAQ:HALO）这样的公司，它不仅有收入，还有利润。这并不是说该公司提供了最佳的投资机会，但盈利能力是商业成功的关键组成部分。</p>
<p>癌症的终结？这 15 只新兴的人工智能股票正在开发技术，以便能够早期识别癌症和阿尔茨海默病等改变生命的疾病。</p>
<h2>Halozyme Therapeutics 的每股收益正在增长</h2>
<p>通常，经历每股收益（EPS）增长的公司，其股价也应呈现类似趋势。因此，有很多投资者喜欢购买每股收益增长的公司的股票。在过去三年中，Halozyme Therapeutics 的每股收益年均增长 8.0%。这可能不是特别高的增长，但确实表明每股收益稳步朝着正确的方向发展。</p>
<p>仔细考虑收入增长和息税前利润（EBIT）利润率，可以帮助判断近期利润增长的可持续性。Halozyme Therapeutics 的股东可以对 EBIT 利润率从 41% 上升到 54% 以及收入增长感到信心。这两方面的表现都令人欣慰。</p>
<p>下图显示了公司底线和顶线随时间的变化。点击图表查看具体数字。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195"/></p>
<p>NasdaqGS:HALO 每股收益和收入历史 2025 年 3 月 29 日</p>
<p>查看我们对 Halozyme Therapeutics 的最新分析</p>
<p>幸运的是，我们可以获取对 Halozyme Therapeutics 未来利润的分析师预测。您可以自己进行预测，也可以看看专业人士的预测。</p>
<h2>Halozyme Therapeutics 的内部人士与所有股东一致吗？</h2>
<p>由于 Halozyme Therapeutics 的市值为 79 亿美元，我们不期望内部人士持有大量股份。但我们对他们投资于公司的事实感到欣慰。内部人士作为一个整体持有价值 8400 万美元的股份，他们在公司的成功上有很大的利益。这应该使他们专注于为股东创造长期价值。</p>
<h2>Halozyme Therapeutics 值得在您的关注名单上占有一席之地吗？</h2>
<p>如前所述，Halozyme Therapeutics 是一家正在成长的企业，这令人鼓舞。如果这还不够，还有相当显著的内部持股水平。这两个因素是该公司的巨大亮点，应该是您关注名单上的强有力竞争者。不过，仍然需要考虑投资风险的无处不在。<strong>我们发现了 Halozyme Therapeutics 的 1 个警示信号</strong>，理解这一点应该是您投资过程的一部分。</p>
<p>尽管 Halozyme Therapeutics 看起来确实不错，但如果内部人士购买股份，可能会吸引更多投资者。如果您喜欢看到更多 “有实质性投入” 的公司，那么请查看这份精心挑选的公司名单，这些公司不仅拥有强劲的增长，还得到了强大的内部支持。</p>
<p><em>请注意，本文讨论的内部交易是指在相关司法管辖区内可报告的交易。</em></p>

奥洛兹美医疗

<p>Halozyme Therapeutics（纳斯达克代码：HALO）因其收入和利润增长而受到关注，成为潜在投资对象。过去三年，该公司的每股收益（EPS）年均增长 8.0%，息税前利润（EBIT）利润率从 41% 上升至 54%。内部人士持有 8400 万美元的股份，表明他们对长期价值创造的承诺。尽管公司前景看好，但投资者仍需对潜在风险保持谨慎，包括一个已识别的警示信号。总体而言，Halozyme Therapeutics 可能是观察名单上的强有力候选者</p>

<p>The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.</p>
<div class="lb-trans"><p>投资于能够扭转命运的公司的兴奋感吸引了一些投机者，因此即使是没有收入、没有利润且业绩不佳的公司，也能找到投资者。但现实是，当一家公司每年亏损足够长的时间后，其投资者通常会承担这些损失。亏损的公司尚未证明其盈利能力，最终外部资本的流入可能会枯竭。</p>
</div><p>In contrast to all that, many investors prefer to focus on companies like <strong>Halozyme Therapeutics</strong> (NASDAQ:HALO), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.</p>
<div class="lb-trans"><p>与此相反，许多投资者更倾向于关注像 <strong>Halozyme Therapeutics</strong>（NASDAQ:HALO）这样的公司，它不仅有收入，还有利润。这并不是说该公司提供了最佳的投资机会，但盈利能力是商业成功的关键组成部分。</p>
</div><p>The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</p>
<div class="lb-trans"><p>癌症的终结？这 15 只新兴的人工智能股票正在开发技术，以便能够早期识别癌症和阿尔茨海默病等改变生命的疾病。</p>
</div><h2>Halozyme Therapeutics' Earnings Per Share Are Growing</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 的每股收益正在增长</h2>
</div><p>Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Over the last three years, Halozyme Therapeutics has grown EPS by 8.0% per year. That might not be particularly high growth, but it does show that per-share earnings are moving steadily in the right direction.</p>
<div class="lb-trans"><p>通常，经历每股收益（EPS）增长的公司，其股价也应呈现类似趋势。因此，有很多投资者喜欢购买每股收益增长的公司的股票。在过去三年中，Halozyme Therapeutics 的每股收益年均增长 8.0%。这可能不是特别高的增长，但确实表明每股收益稳步朝着正确的方向发展。</p>
</div><p>Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Halozyme Therapeutics shareholders can take confidence from the fact that EBIT margins are up from 41% to 54%, and revenue is growing. That's great to see, on both counts.</p>
<div class="lb-trans"><p>仔细考虑收入增长和息税前利润（EBIT）利润率，可以帮助判断近期利润增长的可持续性。Halozyme Therapeutics 的股东可以对 EBIT 利润率从 41% 上升到 54% 以及收入增长感到信心。这两方面的表现都令人欣慰。</p>
</div><p>The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.</p>
<div class="lb-trans"><p>下图显示了公司底线和顶线随时间的变化。点击图表查看具体数字。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195" alt="" original-src="https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195"/></p>
<p>NasdaqGS:HALO Earnings and Revenue History March 29th 2025</p>
<div class="lb-trans"><p>NasdaqGS:HALO 每股收益和收入历史 2025 年 3 月 29 日</p>
</div><p>See our latest analysis for Halozyme Therapeutics</p>
<div class="lb-trans"><p>查看我们对 Halozyme Therapeutics 的最新分析</p>
</div><p>Fortunately, we've got access to analyst forecasts of Halozyme Therapeutics' <em>future</em> profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.</p>
<div class="lb-trans"><p>幸运的是，我们可以获取对 Halozyme Therapeutics 未来利润的分析师预测。您可以自己进行预测，也可以看看专业人士的预测。</p>
</div><h2>Are Halozyme Therapeutics Insiders Aligned With All Shareholders?</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 的内部人士与所有股东一致吗？</h2>
</div><p>Since Halozyme Therapeutics has a market capitalisation of US$7.9b, we wouldn't expect insiders to hold a large percentage of shares. But we are reassured by the fact they have invested in the company. With a whopping US$84m worth of shares as a group, insiders have plenty riding on the company's success. This should keep them focused on creating long term value for shareholders.</p>
<div class="lb-trans"><p>由于 Halozyme Therapeutics 的市值为 79 亿美元，我们不期望内部人士持有大量股份。但我们对他们投资于公司的事实感到欣慰。内部人士作为一个整体持有价值 8400 万美元的股份，他们在公司的成功上有很大的利益。这应该使他们专注于为股东创造长期价值。</p>
</div><h2>Does Halozyme Therapeutics Deserve A Spot On Your Watchlist?</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 值得在您的关注名单上占有一席之地吗？</h2>
</div><p>As previously touched on, Halozyme Therapeutics is a growing business, which is encouraging. If that's not enough on its own, there is also the rather notable levels of insider ownership. These two factors are a huge highlight for the company which should be a strong contender your watchlists. It's still necessary to consider the ever-present spectre of investment risk. <strong>We've identified 1 warning sign</strong> with Halozyme Therapeutics , and understanding this should be part of your investment process.</p>
<div class="lb-trans"><p>如前所述，Halozyme Therapeutics 是一家正在成长的企业，这令人鼓舞。如果这还不够，还有相当显著的内部持股水平。这两个因素是该公司的巨大亮点，应该是您关注名单上的强有力竞争者。不过，仍然需要考虑投资风险的无处不在。<strong>我们发现了 Halozyme Therapeutics 的 1 个警示信号</strong>，理解这一点应该是您投资过程的一部分。</p>
</div><p>Although Halozyme Therapeutics certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.</p>
<div class="lb-trans"><p>尽管 Halozyme Therapeutics 看起来确实不错，但如果内部人士购买股份，可能会吸引更多投资者。如果您喜欢看到更多 “有实质性投入” 的公司，那么请查看这份精心挑选的公司名单，这些公司不仅拥有强劲的增长，还得到了强大的内部支持。</p>
</div><p><em>Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.</em></p>
<div class="lb-trans"><p><em>请注意，本文讨论的内部交易是指在相关司法管辖区内可报告的交易。</em></p>
</div>

现在是时候将奥洛兹美医疗（NASDAQ:HALO）加入你的观察名单了吗？